<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079126</url>
  </required_header>
  <id_info>
    <org_study_id>100-601</org_study_id>
    <nct_id>NCT05079126</nct_id>
  </id_info>
  <brief_title>Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease</brief_title>
  <acronym>ILD-DLCO</acronym>
  <official_title>Double-Blind, Placebo-Controlled Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diffusion Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diffusion Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled study of Trans Sodium Crocetinate (TSC) in patients&#xD;
      with Interstitial Lung Disease (ILD), age 30-85 (inclusive). The primary objective of the&#xD;
      study is to determine the effect of TSC on lung function as measured by diffusing capacity of&#xD;
      the lungs for carbon monoxide (DLCO) in patients with ILD; the secondary objectives are to&#xD;
      determine the effect of TSC on the 6-minute walk test (6MWT), heart rate recovery (HRR), and&#xD;
      Borg Scale in patients with ILD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline at 30 minutes in DLCO after administration of a single dose of TSC versus placebo in patients with ILD</measure>
    <time_frame>30 minutes</time_frame>
    <description>Compare the proportion of patients who achieve a prespecified level of improvement in DLCO 30 minutes after administration of the study drug (TSC or placebo) between the 2 randomized treatment arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 6MWT after administration of a single dose of TSC versus placebo in patients with ILD</measure>
    <time_frame>60 minutes</time_frame>
    <description>Compare the proportion of patients who achieve a pre-specified level of improvement in 6 minute walk test (6MWT) after administration of the study drug (TSC or placebo) between the 2 randomized treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HRR after each 6MWT</measure>
    <time_frame>60 minutes</time_frame>
    <description>Compare the proportion of patients who achieve a pre-specified level of improvement in heart rate recovery (HRR) after administration of the study drug (TSC or placebo) between the 2 randomized treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Borg Scale after the 6MWT</measure>
    <time_frame>60 minutes</time_frame>
    <description>Compare the proportion of patients who achieve a pre-specified level of improvement in the Borg dyspnea scale after administration of the study drug (TSC or placebo) between the 2 randomized treatment arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>2.5 mg/kg Trans Sodium Crocetinate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single IV bolus dose of 2.5 mg/kg TSC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a single IV bolus dose of 7 mL Normal Saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trans Sodium Crocetinate</intervention_name>
    <description>Single IV Bolus</description>
    <arm_group_label>2.5 mg/kg Trans Sodium Crocetinate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single IV Bolus</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female, age 30 to 85 years at screening&#xD;
&#xD;
          2. Able to provide informed consent and agree to adhere to all study visits and&#xD;
             requirements&#xD;
&#xD;
          3. Females of childbearing potential must have a negative blood pregnancy test at&#xD;
             screening and agree to use one of the accepted contraceptive regimens, or a double&#xD;
             method of birth control during the study and at least 30 days after the last dose of&#xD;
             study drug&#xD;
&#xD;
          4. Established diagnosis of ILD (clinical, radiographic, or histologic)&#xD;
&#xD;
          5. SpO2 ≥ 88% at rest by pulse oximetry while breathing ambient air&#xD;
&#xD;
          6. Free of any active cardiovascular or neuromuscular disease, at PI discretion&#xD;
&#xD;
          7. Clinically stable disease with no major medication changes in the last 4 weeks&#xD;
&#xD;
          8. Forced vital capacity (FVC) ≥ 45% of predicted (within past 6 months)&#xD;
&#xD;
          9. DLCO corrected for hemoglobin 30-90% of predicted, inclusive (within past 6 months)&#xD;
&#xD;
         10. Sars-CoV-2 negative at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy to study medication&#xD;
&#xD;
          2. Pregnancy or lactation&#xD;
&#xD;
          3. Current smoker&#xD;
&#xD;
          4. Inability to perform pulmonary function testing&#xD;
&#xD;
          5. Active infection at screening or day of study visit&#xD;
&#xD;
          6. Known pulmonary hypertension (PH) requiring PH-specific treatment&#xD;
&#xD;
          7. AST/ALT ≥ 3x ULN and/or total bilirubin ≥ 2x ULN&#xD;
&#xD;
          8. Received any investigational medicine (IMP) within past 30 days&#xD;
&#xD;
          9. Surgery or hospitalization in past 3 months determined by the PI to be clinically&#xD;
             relevant.&#xD;
&#xD;
         10. Current alcohol or substance abuse&#xD;
&#xD;
         11. Known active or latent hepatitis B or C&#xD;
&#xD;
         12. History of end-stage liver or renal disease&#xD;
&#xD;
         13. Positive COVID test anytime within 3 months of screening. Note:&#xD;
&#xD;
             Patients who were previously vaccinated for COVID are allowed&#xD;
&#xD;
         14. History of venous thromboembolic disease&#xD;
&#xD;
         15. History of acute or chronic ophthalmologic conditions currently requiring treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kelly Arscott</last_name>
    <phone>(434) 220-0718</phone>
    <email>karscott@diffusionpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chris Galloway, MD</last_name>
    <phone>(434) 220-0718</phone>
    <email>cgalloway@diffusionpharma.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trans-sodium crocetinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

